The future of TNF-α antagonism

Future Rheumatology

Volumn 2, Issue 3, 2007, Pages 233-236

  Taylor, Peter C ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SORAFENIB; SUNITINIB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADJUVANT THERAPY; BIOTECHNOLOGY; CELL SUBPOPULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ACTIVITY; DISEASE COURSE; DRUG COST; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; DRUG WITHDRAWAL; EDITORIAL; GENETIC ENGINEERING; HUMAN; INFECTION; KIDNEY CARCINOMA; LIVER DYSFUNCTION; MEDICAL RESEARCH; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RHEUMATOID ARTHRITIS; SYMPTOM; SYNOVITIS; TREATMENT OUTCOME;

EID: 34347376515     PISSN: 17460816     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460816.2.3.233     Document Type: Editorial

References (27)

1. Klareskog L, van der Heijde D, de Jager JP et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: do4uble-blind randomised controlled trial. Lancet 363(9410), 675-681 (2004).
2. Lipsky PE, van der Heijde DM, St Clair EW et al.: Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group: infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med. 343(22), 1594-1602 (2000).
3. Smolen JS, Han C, Bala M et al.: Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum, 52(4). 1020-1030 (2005).
4. Hazleman B, Smith M, Moss K et al.: Efficacy of a novel pegylated humanised anti-TNF fragment (CDP870) in patients with rheumatoid arthritis. Rheumatology 39(Suppl. 1). Abstracts (2000).
5. Taylor PC: Pharmarcotherapeutics in rheumatoid arthritis. In: Rheumatoid Arthritis in Practice. Royal Society of Medicine Press Ltd, (1st Edition). London, UK 49-69 (2006).
6. Smolen JS, Aletaha D, Keystone E: Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction? Arthritis Rheum. 52(10), 2975-2983 (2005).
7. Boers M, Verhoeven AC, Markusse HM et al.: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350(9074), 309-318 (1997).
8. Landewe RB, Boers M, Verhoeven AC et al.: COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 46(2), 347-356 (2002).
9. van Dongen H, van Aken J, Lard LR et al.: Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 56(5), 1424-1432 (2007).
10. Grigor C, Capell H. Stirling A et al.: Effect of a treatment strategy of tight control for rheumatoid arthritis(the TICORA study): a single-blind randomised controlled trial. Lancet 364(9430), 263-269 (2004).
11. Breedveld FC, Weisman MH, Kavanaugh AF et al.: The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54(1), 26-37 (2006).
12. St Clair EW, van der Heijde DM, Smolen JS et al.: Active-controlled study of Patients receiving infliximab for the treatment of rheumatoid arthritis of early onset study group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized. controlled trial. Arthritis Rheum. 50(11), 3432-3443 (2004).
13. Klareskog L, van der Heijde D, de Jager JP et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410), 675-681 (2004).
14. Taylor PC, Steuer A, Gruber J et al.: Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum. 50(4). 1107-1116 (2004).
15. Taylor PC, Steuer A, Gruber J et al.: Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum. 54 (1), 47-53 (2006).
16. Quinn MA, Conaghan PG, O'Connor PJ et al.: Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 52(1), 27-35 (2005).
17. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 52 (11), 3381-3390 (2005).
18. van der Biji AE, van der Kooij SM, Goekoop-Ruiterman YP et al.: Persistent good clinical response after tapering and discontinuation of initial infliximab therapy in patients with early rheumatoid arthritis: 3 year results of the BEST trial. Ann. Rheum. Dis. 65(Suppl 2), 109 (2006).
19. Choy EH, Smith C, Dore CJ, Scott DL: A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford). 44(11), 1414-1421 (2005).
20. Genovese MC, Cohen S, Moreland L et al.: Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 50(5), 1412-1419 (2004).
21. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E: Safety of the selective co-stimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum. 54 (9), 2807-2816 (2006).
22. Weinblatt M, Schiff M, Goldman A et al.: Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann. Rheum. Dis. 66(2), 228-234 (2007).
23. Williams RO, Marinova-Mutafchieva L, Feldmann M, Maini RN: Evaluation of TNF-α and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-α/anti-CD4 therapy. J. Immunol. 165(12), 7240-7245 (2000).
24. Mbalaviele G, Anderson G. Jones A et al.: Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction. J. Pharmacol. Exp. Ther. 317(3), 1044-1053 (2006).
25. Ding C: Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr. Opin. Investig. Drugs. 7(11). 1020-1025 (2006).
26. Thabet MM, Huizinga TW: Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Curr. Opin. Investig. Drugs 7(11), 1014-1019 (2006).
27. Yamamoto S, Sugahara S, Ikeda K, Shimizu Y: Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059. Eur. J. Pharmacol. 559(2-3), 219-226 (2007).